Physician profile
Ashwani Singal
NPI 1609036896
$123,469.09
in general payments reported to CMS, 2019-2025
18 companies · $96K in 2025
The $96K reported for 2025 was more than what 94% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.01 · 2021: $1,014 · 2022: $6,075 · 2023: $2,546 · 2024: $18K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Consulting Fee: $15K · Travel and Lodging: $13K · Food and Beverage: $3,720 · Honoraria: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,495.00 |
| Consulting Fee | $14,710.00 |
| Travel and Lodging | $13,431.54 |
| Food and Beverage | $3,719.67 |
| Honoraria | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $106,685.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Tanabe Pharma America, INC. | $3,475.00 | 2022 | |
| Orphalan INC | $3,000.00 | 2024 | Cuvrior |
| Glaxosmithkline, LLC. | $2,600.00 | 2022 | |
| Siemens Medical Solutions USA, INC. | $2,397.00 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $2,395.57 | 2025 | Iqirvo |
| Spectrum Pharmaceuticals INC. | $1,310.00 | 2025 | Rolvedon |
| Alexion Pharmaceuticals, INC. | $1,000.00 | 2021 | |
| Gilead Sciences, INC. | $202.16 | 2021-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.38 | 2023 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $125.53 | 2025 | Terlivaz |
| Novo Nordisk INC | $88.29 | 2025 | |
| Abbvie INC. | $24.01 | 2019 | |
| Albireo Pharma, INC. | $16.90 | 2024 | Bylvay |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwani Singal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.